Bicara Therapeutics Reports Q2 2026 Quarterly Results

What Happened

• On August 11, 2026, Bicara Therapeutics Inc. (BCAX) filed a Form 8-K (Items 2.02 and 9.01) to announce its results of operations and financial condition for the quarter ended June 30, 2026 and to furnish a press release with other business updates.
• The full press release is furnished as Exhibit 99.1 to the 8-K (dated August 11, 2026) and the filing includes the Interactive XBRL cover page (Exhibit 104). The filing is signed by CEO Claire Mazumdar.

Key Details

• Filing date: August 11, 2026 (Form 8-K, Items 2.02 and 9.01).
• Reporting period: Quarter ended June 30, 2026 (Q2 2026).
• Press release: Exhibit 99.1 to the 8-K (contains the detailed financial results and business updates).
• Signature: Filed and signed on behalf of the company by Claire Mazumdar, Chief Executive Officer.

Why It Matters

• This 8-K provides Bicara’s latest quarterly results and business updates—material information for investors assessing recent earnings, revenue, cash position, and program progress.
• The 8-K text references the press release for the detailed figures; investors should review Exhibit 99.1 (and any subsequent filings or investor materials) to see the specific financial metrics and operational disclosures.